Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
| Excerpt | Reference |
|---|
| "A case of primary pulmonary hypertension is described in which terbutaline sulfate and indomethacin were given a trial." | ( Person, B; Proctor, RJ, 1979) |
| "Pulmonary hypertension is one of the major problems in the neonatal period." | ( Lakatos, L; Oroszlán, G; Sanderud, J; Saugstad, OD, 1992) |
| "Pulmonary hypertension is the most frequent cause of death in patients with mixed connective tissue disease." | ( Calverley, D; Chalmers, A; Dahl, M; Munt, B; Wade, J, 1992) |
| "Primary pulmonary hypertension is a progressive, fatal disease of unknown cause." | ( Kaufmann, E; Levy, PS; Rich, S, 1992) |
| "Pulmonary hypertension is probably the most important consequence of long-standing hypoxaemia and, in our opinion, the presence and the degree of PH should be assessed in every patient before starting such a heavy therapy as LTO." | ( Apprill, M; Ehrhart, M; Oswald, M; Weitzenblum, E, 1990) |
| "Chronic pulmonary hypertension is associated with extensive structural remodeling of the pulmonary arterial bed." | ( Brigham, KL; Lyons, RM; Meyrick, B; Moses, HL; Perkett, EA, 1990) |
| "Primary pulmonary hypertension is an uncommon but serious disease that often results in debilitating symptoms and early death." | ( Aimè, E; Angoli, L; Arbustini, E; Bargiggia, G; Campana, C; Gavazzi, A; Graziano, G; Lanzarini, L; Montemartini, C; Mussini, A, 1990) |
| "Pulmonary hypertension is associated with abnormal connective tissue deposition in the media of pulmonary arteries." | ( Chang, D; Crouch, EC; Mecham, RP; Orton, EC; Parks, WC; Rosenbaum, JL; Stenmark, KR; Whitehouse, L; Wu, LJ, 1989) |
| "Primary pulmonary hypertension is a disease of unknown etiology." | ( Petersen, TI; Svanegård, J; Thayssen, P, 1989) |
| "Primary pulmonary hypertension is a rare disease entity." | ( Abe, S; Akaishi, M; Handa, S; Hosoda, Y; Iwanaga, S; Nakamura, Y; Onishi, S; Yamada, T; Yoshikawa, T; Yoshimura, Y, 1989) |
| "Early reversal of pulmonary hypertension is possible, and intervention is desirable before the establishment of chronic hypoxia, cor pulmonale, or right ventricular failure." | ( Bossuyt, A; Dab, I; Davidson, A, 1989) |
| "Pulmonary hypertension is associated with an increased perioperative mortality for orthotopic heart transplantation." | ( Bolling, SF; Deeb, GM; Guynn, TP; Nicklas, JM, 1989) |
| "The therapy of pulmonary hypertension is difficult in those diseases where the causes or mechanisms are not understood or are unknown." | ( Denolin, H; Mathey, DG, 1986) |
| "Thus, in ARDS, pulmonary hypertension is reduced by PGE1 at the price of a deterioration in pulmonary gas exchange." | ( Leeman, M; Lejeune, P; Mélot, C; Moraine, JJ; Naeije, R, 1989) |
| "We conclude that pulmonary hypertension is probably a result of chronic hypoxemia experienced by patients with pulmonary hemosiderosis." | ( Frankel, LR; Lewiston, NJ; Pearl, RG; Smith, DW, 1986) |
| "Primary pulmonary hypertension is a rare and fatal disease." | ( Cheng, DC; Edelist, G, 1988) |
| "Secondary pulmonary hypertension is seen in disorders that either interfere with gas exchange within the lung or in which large portions of the pulmonary vasculature are obliterated." | ( Peil, ML; Rubin, LJ, 1986) |
| "Primary pulmonary hypertension is an uncommon but serious disease that often results in debilitating symptoms and early death." | ( McGoon, MD; Vlietstra, RE, 1984) |
| "Therapy of pulmonary hypertension is limited by the low potency and adverse effects of current pulmonary vasodilators." | ( Ashton, JP; Pearl, RG; Rosenthal, MH; Schroeder, JS, 1983) |
| "Pulmonary hypertension is an unusual complication of portal hypertension that is being reported increasingly often." | ( Abraham, JL; Molden, D, 1982) |
| "Primary pulmonary hypertension is an irreversible and fatal disorder." | ( Frankl, O; Goldhammer, E; Kaplinsky, N; Olchovsky, D; Pines, A, 1982) |
| "Pulmonary hypertension is known to occur at high altitudes, due to hypoxia and is considered to be more common in women taking oral contraceptives, situations known to decrease the synthesis of prostaglandin E and possibly prostacyclin with simultaneous increase in thromboxane A2 synthesis." | ( Das, UN, 1980) |
| "Severe pulmonary hypertension is still a cause of morbidity and mortality in children after cardiac operations." | ( Deanfield, JE; Delius, RE; Goldman, AP; Macrae, DJ, 1995) |
| "Drug-induced pulmonary hypertension is rare but has been reported relatively often after use of the sympathicomimetic agent aminorexfumarate, but also, although more rarely, of fenfluramine." | ( Maesen, BL; Snijder, RJ; Stricker, BH, 1994) |
| "Primary pulmonary hypertension is a rare, incurable, and progressive disease." | ( Asseryanis, E; Egarter, C; Kiss, H; Kneussl, M; Putz, D, 1995) |
| "Primary pulmonary hypertension is a rare disease with a median survival of only 2." | ( Solèr, M, 1994) |
| "Chronic pulmonary hypertension is associated with significant vascular remodeling." | ( Arend, WP; Bridges, J; Tuder, RM; Voelkel, NF, 1994) |
| "Pulmonary hypertension is a major complication of congenital diaphragmatic hernia (CDH)." | ( Albanese, C; Billiar, T; Exler, R; Ford, H; Jacob, T; Morrow, S; Rowe, M; Shah, N; Simmons, R; Wiener, E, 1994) |
| "Thromboembolic pulmonary hypertension is an uncommon condition with poor prognosis." | ( Fijałkowska, A; Filipecki, S; Hajduk, B; Pałasiewicz, G; Polowiec, Z; Radomyski, A; Tomkowski, W, 1994) |
| "Pulmonary hypertension is an uncommon complication of portal hypertension seen in cirrhotic as well as noncirrhotic patients." | ( Hayashi, S; Iwai, N; Nakamura, K; Onouchi, Z; Shiraishi, I; Tokiwa, K, 1993) |
| "Pulmonary hypertension is commonly encountered in Intensive Care Units and the effects on right ventricular function are often a cause for concern." | ( Sykes, MK, 1994) |
| "Pulmonary hypertension is usually mild (between 20 and 35 mmHg) in COPD patients, but pulmonary artery pressure (PAP) may increase markedly and suddenly during exercise, sleep and episodes of acute respiratory failure." | ( Adnot, S; Samoyeau, R; Weitzenblum, E, 1995) |
| "Pulmonary hypertension is the major hemodynamic feature of progressive lung injury." | ( Fullerton, DA; Hahn, AR; McIntyre, RC, 1996) |
| "Pulmonary hypertension is a hallmark of high-altitude pulmonary edema and may contribute to its pathogenesis." | ( Ballmer, PE; Bärtsch, P; Delabays, A; Eichenberger, U; Fikrle, A; Kleger, GR; Nicod, P; Savcic, M; Scherrer, U; Vollenweider, L, 1996) |
| "Pulmonary hypertension is a serious complication after cardiopulmonary bypass (CPB)." | ( Buckberg, GD; Ignarro, LJ; Ihnken, K; Morita, K; Sherman, MP, 1996) |
| "Postoperative pulmonary hypertension is a life-threatening, yet reversible complication of congenital heart operations." | ( de Leval, MR; Deanfield, JE; Delius, RE; Goldman, AP; Macrae, DJ; Sigston, PE, 1996) |
| "Pulmonary hypertension is usually treated with intravenous (i." | ( Blaise, G; Charbonneau, M; Collet, JP; da Silva, P; Ducruet, T; Jacob, E; Salazkin, I; Troncy, E, 1996) |
| "Fixed pulmonary hypertension is a risk factor for right heart failure and death after orthotopic heart transplantation." | ( Colucci, WS; Gauthier, DF; Givertz, MM; Hare, JM; Loh, E, 1996) |
| "Pulmonary hypertension is a well known, though uncommon complication of end-stage liver disease (ESLD)." | ( East, CA; Hein, HA; Klintmalm, GB; Lynch, K; Nguyen, AT; Ramsay, KJ; Ramsay, MA; Schmidt, A, 1997) |
| "Although post-CPB pulmonary hypertension is well described, its mechanisms remain incompletely understood." | ( Fineman, JR; Hanley, FL; Hendricks-Munoz, KD; Petrossian, E; Rajasinghe, HA; Reddy, VM, 1997) |
| "Progressive pulmonary hypertension is characterized by smooth muscle cell proliferation and migration leading to occlusive arterial lesions." | ( Cowan, KN; Jones, PL; Rabinovitch, M, 1997) |
| "Chronic pulmonary hypertension is difficult to treat and despite the introduction of several therapeutic options, no single therapy is universally recommended." | ( Bittner, HB; Chen, EP; Craig, D; Davis, RD; Tull, F; Van Trigt, P, 1997) |
| "A stable model of pulmonary hypertension is provided as a potential means to evaluate posttransplantation RV dysfunction in the setting of CPH." | ( Biswas, SS; Bittner, HB; Chen, EP; Davis, RD; Tull, F; Van Trigt, P, 1997) |
| "Neonatal pulmonary hypertension is associated with increased pulmonary vascular reactivity." | ( Boels, PJ; Deutsch, J; Haworth, SG; Hislop, AA; Tulloh, RM, 1997) |
| "Pulmonary hypertension is associated with endothelial dysfunction that may mediate or contribute to the disease process; among those abnormalities is an increase in circulating endothelin-1 levels." | ( Cernacek, P; Dupuis, J; Leung, TK; Prié, S; Ryan, JW, 1997) |
| "Pulmonary hypertension is responsible for a substantial part of perioperative and postoperative mortality and morbidity after cardiac transplantation." | ( Bauer, J; Dapper, F; Demirakça, S; Hagel, KJ; Knothe, C; Thul, J, 1997) |
| "Pulmonary hypertension is characterized by increased vascular resistance due to smooth muscle cell hyper-activity and excess deposition of extracellular matrix (ECM) in the vessel wall." | ( Ingber, DE; Lee, KM; Tsai, KY; Wang, N, 1998) |
| "Pulmonary hypertension is a debilitating disease that occurs among infants and adults." | ( Ekman, R; Keith, IM; Kraiczi, H; Tjen-A-Looi, S, 1998) |
| "Pulmonary hypertension is an important cause of mortality in infants with congenital diaphragmatic hernia (CDH)." | ( Au-Fliegner, M; Coppola, CP; Gosche, JR, 1998) |
| "Primary pulmonary hypertension is a rare, progressive and incurable disease, which has been associated with the intake of appetite suppressant drugs." | ( Delcroix, M; Demedts, M; Kurz, X; Naeije, R; Walckiers, D, 1998) |
| "Pulmonary hypertension is a progressive disease for which no effective therapy has been found." | ( Fukushima, S; Kunieda, T; Kyotani, S; Nakanishi, N; Okano, Y; Satoh, T; Satomi, K, 1998) |
| "Primary pulmonary hypertension is a rare clinical disorder which carries a bad prognosis." | ( Fernandez-Infante, B; Fernandez-Rozas, S; Golpe, R, 1998) |
| "Primary pulmonary hypertension is a disease with a high mortality rate and for which there is no satisfactory medical treatment." | ( Koh, E; Nakamura, T; Niimura, J; Takahashi, H; Yamakage, H, 1998) |
| "Primary pulmonary hypertension is a clinical syndrome with severe pulmonary hypertension where other causal diseases are excluded." | ( Hågå, P; Hankø, E, 1999) |
| "Early diagnosis of pulmonary hypertension is critical." | ( Easterling, TR; Ralph, DD; Schmucker, BC, 1999) |
| "A mild degree of pulmonary hypertension is commonly observed in patients with acute respiratory distress syndrome (ARDS)." | ( Leeman, M, 1999) |
| "Pulmonary hypertension is a life-threatening complication of lung fibrosis." | ( Ghofrani, HA; Grimminger, F; Olschewski, H; Schermuly, R; Seeger, W; Temmesfeld-Wollbruck, B; Walmrath, D, 1999) |
| "Exaggerated pulmonary hypertension is a hallmark of HAPE and is thought to play an important part in its pathogenesis." | ( Allemann, Y; Duplain, H; Lepori, M; Nicod, P; Sartori, C; Scherrer, U; Trueb, L, 1999) |
| "Pulmonary hypertension is a progressive and often fatal complication of the scleroderma spectrum of disease for which no treatment has been proven effective in a randomized trial." | ( Badesch, DB; Barrett, PS; Barst, RJ; Bourge, RC; Brundage, BH; Elliott, CG; Frost, A; Girgis, R; Groves, BM; Hill, NS; Jöbsis, MM; Kral, KM; Langleben, D; Loyd, JE; McGoon, MD; McLaughlin, VV; Medsger, TA; Murali, S; Ralph, DD; Rich, S; Robbins, IM; Rubin, LJ; Schilz, RJ; Shapiro, S; Tapson, VF; Wigley, FM, 2000) |
| "Pulmonary hypertension is a life-threatening complication of lung fibrosis." | ( Ghofrani, HA; Grimminger, F; Olschewski, H; Schermuly, R; Seeger, W; Temmesfeld-Wollbrück, B; Walmrath, D, 2000) |
| "Progression of pulmonary hypertension is associated with increased serine elastase activity and the proteinase-dependent deposition of the extracellular matrix smooth muscle cell survival factor tenascin-C (refs." | ( Cowan, KN; Heilbut, A; Humpl, T; Ito, S; Lam, C; Rabinovitch, M, 2000) |
| "Pulmonary hypertension is uncommonly associated with portal hypertension." | ( Angrill, J; Barberà, JA; Bosch, J; García-Pagán, JC; Ribas, J; Roca, J; Rodriguez-Roisin, R, 1999) |
| "Primary pulmonary hypertension is a rare disease of childhood, which carries a poor prognosis." | ( Abrams, D; Magee, AG; Schulze-Neick, I, 2000) |
| "Pulmonary hypertension is associated with congenital heart lesions with increased pulmonary blood flow." | ( Adatia, I; Beghetti, M; Bohn, D; Morris, K; Petros, A, 2000) |
| "Chronic pulmonary hypertension is a serious complication of a number of chronic lung and heart diseases." | ( Hampl, V; Herget, J, 2000) |
| "More severe pulmonary hypertension is associated with higher ET-1 concentrations, but whether ET-1 is a marker or a mediator of pulmonary hypertension remains as yet unsettled." | ( Baan, J; de Vroomen, M; Frölich, M; Lopes Cardozo, RH; Steendijk, P; van Bel, F, 2001) |
| "Primary pulmonary hypertension is a rare disease in childhood associated with a poor prognosis." | ( Beghetti, M; Berner, M; Rimensberger, PC, 2001) |
| "Primary pulmonary hypertension is a rare and dangerous entity in pregnancy." | ( Cairns, BA; Lam, GK; Moise, KJ; Stafford, RE; Thorp, J, 2001) |
| "Pulmonary hypertension is an uncommon feature of Whipple's disease and the underlying pathophysiological mechanism remains a subject of debate." | ( Bergheul, S; Brinkane, A; Crickx, L; Gaudin, B; Levy, R; Morcelet, M; Peschard, S, 2001) |
| "Pulmonary hypertension is associated with changes in vascular tone as well as vascular structure, with the relative contribution of each dependent upon the aetiology of the increased pulmonary vascular resistance." | ( Brock, TA; Dixon, RA; Tilton, RG, 2001) |
| "Persistent pulmonary hypertension is seen in association with a number of diseases and conditions in the newborn including perinatal asphyxia, meconium aspiration syndrome, Group B strep sepsis, and certain surgical conditions such as congenital diaphragmatic hernia." | ( Cook, LN, 2002) |
| "Pulmonary hypertension is a life-threatening disease characterized by an increase in artery pressure and vascular resistance in the pulmonary circulation." | ( Gessler, T; Grimminger, F; Olschewski, H; Schmehl, T; Seeger, W, 2002) |
| "Primary pulmonary hypertension is a progressive and often fatal disorder in humans that results from an increase in pulmonary blood pressure associated with abnormal vascular proliferation." | ( Callebert, J; Drouet, L; Etienne, N; Hervé, P; Humbert, M; Launay, JM; Maroteaux, L; Nebigil, CG; Peoc'h, K; Simonneau, G; Tournois, C, 2002) |
| "Pulmonary hypertension is a hemodynamic abnormality that is common to a variety of conditions." | ( Mandegar, M; Yuan, JX, 2002) |
| "Pulmonary hypertension is a common complication of chronic obstructive airways disease (COPD) and its presence implies a poor prognosis." | ( Brown, A; Patel, KR; Peacock, AJ; Raeside, DA; Welsh, D, 2002) |
| "Significant pulmonary hypertension is a predictor of postoperative right heart insufficiency and increased mortality in patients undergoing orthotopic heart transplantation." | ( Czeslick, E; Dehne, MG; Friedrich, I; Grond, S; Hentschel, T; Mühling, J; Sablotzki, A; Schubert, S, 2002) |
| "Pulmonary hypertension is associated with various alterations in 5-hydroxytryptamine (5-HT) physiology." | ( Awabdy, D; Bryan-Lluka, LJ; Wanstall, JC, 2003) |
| "Pulmonary hypertension is a life-threatening complication of sickle cell disease." | ( Claster, S; Hagar, W; Kepka-Lenhart, D; Kuypers, FA; Machado, L; Morris, CR; Morris, SM; Van Warmerdam, J; Vichinsky, EP, 2003) |
| "Pulmonary hypertension is a frequent complication of severe chronic obstructive pulmonary disease (COPD) and a major cause of morbidity and mortality in this condition." | ( Block, LH; Germann, P; Higenbottam, TW; Petkov, V; Schenk, P; Stiebellehner, L; Vonbank, K; Ziesche, R, 2003) |
| "Primary pulmonary hypertension is a fatal disease causing progressive right heart failure within 3 years after diagnosis." | ( Block, LH; Burian, B; Funk, GC; Hamilton, G; Mosgoeller, W; Novotny, C; Petkov, V; Raderer, M; Stiebellehner, L; Vonbank, K; Ziesche, R, 2003) |
| "Portopulmonary hypertension is common in cirrhosis with refractory ascites, possibly due to excess endothelin 1 in the pulmonary circulation." | ( Benjaminov, FS; Liu, P; Prentice, M; Siu, S; Sniderman, KW; Wong, F, 2003) |
| "Primary pulmonary hypertension is a fatal disease characterized by endothelial dysfunction, hypercontraction and proliferation of vascular smooth muscle cells (VSMCs), and migration of inflammatory cells, for which no satisfactory treatment has yet been developed." | ( Abe, K; Hattori, T; Kaibuchi, K; Matsumoto, Y; Morikawa, K; Nakashima, Y; Oi, K; Shimokawa, H; Sueishi, K; Takeshit, A; Uwatoku, T, 2004) |
| "Poor survival in pulmonary hypertension is known to be associated with unfavorable hemodynamic variables, including elevated right atrial pressure, elevated mean pulmonary artery pressure, and low cardiac index." | ( Armstrong, R; Fouad-Tarazi, F; James, KB; Stelmach, K; Young, JB, 2003) |
| "Severe pulmonary hypertension is one of the fetal complications in various connective tissue diseases." | ( Ide, H; Kikuchi, K; Nakagawa, N; Nakano, H; Nishigaki, Y; Obata, H; Ohsaki, Y; Osanai, S; Takahashi, S; Tokusashi, Y, 2003) |
| "Primary pulmonary hypertension is a progressive disease leading to right heart failure and death." | ( Baumgartner, RA; Behr, J; Ding, I; Holzapfel, M; Kolbe, T; Leuchte, HH; Neurohr, C; Schwaiblmair, M; Vogeser, M, 2004) |
| "Pulmonary hypertension is a significant problem to take into account in the post-operative management of cardiac patients, especially valvular patients." | ( Abecassis, M; Baptista, P; Queiroz e Melo, J; Rebocho, MJ; Timóteo, AT, 2003) |
| "Pulmonary hypertension is an integral part of the pathophysiology of the respiratory failure associated with congenital diaphragmatic hernia." | ( Cilley, RE; Dillon, PW; Mauger, D; Meier, A; Zachary, C, 2004) |
| "The evolution of pulmonary hypertension is a critical determinant of survival in CDH patients with current treatment strategies." | ( Cilley, RE; Dillon, PW; Mauger, D; Meier, A; Zachary, C, 2004) |
| "Primary pulmonary hypertension is a rare disease of the pulmonary vasculature manifested by dyspnea on exertion, syncope, and signs and symptoms of right heart failure." | ( Poon, M; Sulica, R, 2004) |
| "Severe pulmonary hypertension is a disabling disease with high mortality." | ( Ermert, L; Ghofrani, HA; Grimminger, F; Kreisselmeier, KP; Pullamsetti, S; Samidurai, A; Schermuly, RT; Schudt, C; Seeger, W; Weissmann, N, 2004) |
| "Primary pulmonary hypertension is a disorder with limited treatment options." | ( Narasimhan, C; Raju, BS; Reddy, NK; Sastry, BK, 2004) |
| "Pulmonary hypertension is an uncommon, yet devastating, syndrome with a complex underlying pathobiology." | ( Loscalzo, J; Napoli, C, 2004) |
| "Pulmonary hypertension is a main pathogenetic factor underlying chronic corpulmonale formation." | ( Metliaeva, NA, 2004) |
| "Pulmonary hypertension is a proliferative vascular disease characterized by pulmonary vascular structural remodeling." | ( Fu, LJ; Li, F; Shen, J; Zhao, W; Zhou, AQ, 2004) |
| "Acute neonatal pulmonary hypertension is associated with increased activation of the endogenous endothelin pathway." | ( Penny, DJ; Ravn, HB; Reader, JA; Ryhammer, PK; Shekerdemian, LS, 2004) |
| "HIV-related pulmonary hypertension is a clinical disorder which carries a bad prognosis." | ( Borgia, MC; D'Ambrosio, C; Pellicelli, AM; Pino, P; Soccorsi, F; Tanzi, P; Vizza, CD; Zachara, E, 2004) |
| "Chronic hypoxic pulmonary hypertension is associated with profound vascular remodeling and alterations in Ca(2+) homeostasis in pulmonary arterial smooth muscle cells (PASMCs)." | ( Leung, GP; Lin, MJ; Sham, JS; Tse, CM; Yang, XR; Yip, KP; Zhang, WM, 2004) |
| "Pulmonary hypertension is a major risk factor in cardiac surgery and has significant impact on morbidity and mortality in the perioperative period." | ( Langer, F; Lausberg, H; Schäfers, HJ; Wilhelm, W, 2004) |
| "While pulmonary hypertension is usually not associated with AOS, the abnormal endothelial regulation of vascular tone seen in the pulmonary vasculature may enhance current pathophysiologic concepts of vascular abnormalities in AOS." | ( Blackston, D; Piazza, AJ; Sola, A, 2004) |
| "In conclusion, portopulmonary hypertension is a relative contraindication to orthotopic liver transplantation, which should be attempted only if pulmonary haemodynamics improve with prostanoids." | ( Clavien, PA; Fischler, M; Jenni, R; Minder, S; Muellhaupt, B; Speich, R; Zalunardo, MP, 2004) |
| "Pulmonary hypertension is not a rare pathology that is met in a doctor's practice." | ( Barkauskiene, D; Sadauskas, S; Sakalauskas, R; Vebriene, J, 2004) |
| "Pulmonary hypertension is an early sign of potentially fatal disease and can cause failure of conventional respiratory therapy in severe acute respiratory distress syndrome (ARDS)." | ( Frühwirth, M; Horak, E; Maurer, H; Simma, B; Skladal, D, 2004) |
| "Portopulmonary hypertension is a poorly understood and uncommon complication of advanced chronic liver disease." | ( Chua, R; Keogh, A; Miyashita, M, 2005) |
| "Pulmonary hypertension is a fatal disease characterized by vasoconstriction and vascular remodeling." | ( Alp, NJ; Bendall, JK; Channon, KM; Khoo, JP; Nicoli, T; Rockett, K; Wilkins, MR; Zhao, L, 2005) |
| "The treatment of pulmonary hypertension is challenging." | ( Chiao, TB; Lee, AJ; Tsang, MP, 2005) |
| "Severe pulmonary hypertension is uncommon in patients with COPD." | ( Bugnet, AS; Chaouat, A; Ducoloné, A; Ehrhart, M; Enache, I; Kadaoui, N; Kessler, R; Schott, R; Weitzenblum, E, 2005) |
| "Pulmonary hypertension is a devastating complication of various, but rare diseases and can also occur as an isolated entity." | ( Bredie, SJ; Heijdra, YF; van den Hoogen, FH; van der Heijden, HF; van Dijk, AP; Vonk, MC, 2005) |
| "Pulmonary hypertension is a frequent complication of sickle cell disease that is associated with haemolysis, impaired nitric oxide bioavailability and high mortality." | ( Anthi, A; Barst, RJ; Castro, O; Coles, W; Gladwin, MT; Hunter, C; Hunter, L; Kato, GJ; Machado, RF; Martyr, S; Nichols, J; Robinson, MR; Sachdev, V, 2005) |
| "Pulmonary hypertension is a common complication of chronic obstructive pulmonary disease (COPD)." | ( Naeije, R, 2005) |
| "Progression of pulmonary hypertension is associated with increased proliferation and migration of pulmonary vascular smooth muscle cells." | ( Dony, E; Ghofrani, HA; Grimminger, F; Lai, YJ; Pullamsetti, S; Roth, M; Savai, R; Schermuly, RT; Seeger, W; Sydykov, A; Weissmann, N, 2005) |
| "Pulmonary hypertension is prevalent in adult patients with sickle cell disease and is strongly associated with early mortality and markers of hemolysis, in particular, serum lactate dehydrogenase (LDH)." | ( Gladwin, MT; Kato, GJ; Little, JA; Machado, RF; McGowan, V; Morris, CR; Morris, SM; Nichols, JS; Poljakovic, M; Taylor, J; Wang, X, 2006) |
| "Pulmonary hypertension is a known complication of sarcoidosis." | ( Foley, RJ; Metersky, ML, 2008) |
| "Perioperative pulmonary hypertension is a challenging clinical problem with numerous etiologies including hypoxia, adrenergic stimulation, and local inflammation." | ( Brown, JW; Fiore, AC; Meldrum, DR; Sheridan, BC; Tsai, BM; Turrentine, MW; Wang, M, 2006) |
| "Severe pulmonary hypertension is a disabling disease with high mortality, characterized by pulmonary vascular remodeling and right heart hypertrophy." | ( Beuerlein, K; Dony, E; Dumitrascu, R; Ghofrani, HA; Gnoth, MJ; Grimminger, F; Schermuly, RT; Schmidt, H; Seeger, W; Stasch, JP; Weissmann, N, 2006) |
| "Pulmonary hypertension is characterized by high pulmonary blood pressure, vascular remodeling, and right ventricular hypertrophy." | ( Fukuchi, Y; Homma, N; Morio, Y; Muramatsu, M; Sato, K; Suzuki, T; Takahashi, H; Yamamoto, A, 2006) |
| "Pulmonary hypertension is a rare disease of the pulmonary vasculature defined as a mean pulmonary artery pressure >25 mmHg at rest or 30 mmHg with exercise." | ( Channer, KS; Jones, RD; Smith, AM, 2006) |
| "Pulmonary hypertension is associated with remodeling of the smooth muscle layer of pulmonary arteries, manifested by reduced smooth muscle cell (SMC) contractility and enhanced motility and growth." | ( Bongalon, S; Dai, YP; Mutafova-Yambolieva, VN; Parks, SD; Tian, H; Yamboliev, IA, 2006) |
| "Severe pulmonary hypertension is the one of critical postoperative complications for congenital MS with PDA cases." | ( Nakamura, Y; Nomura, K; Uno, Y; Yamashiro, M, 2006) |
| "Pulmonary hypertension is common in adults with thalassaemia and other haemolytic anaemias." | ( Hagar, RW; Morris, CR; Vichinsky, EP, 2006) |
| "Pulmonary hypertension is a common complication of beta-thalassemia major." | ( Farber, HW; Tam, DH, 2006) |
| "Pulmonary hypertension is a devastating disorder, characterized by vascular proliferation, intimal hypertrophy and vasoconstriction." | ( Champion, HC; Hemnes, AR, 2006) |
| "Pulmonary hypertension is a complicated and important pathological process in the development of a variety of cardiovascular and pulmonary diseases, and directly affects the development of the diseases and their prognosis." | ( Du, JB; Jin, HF; Tang, CS; Wang, YF, 2006) |
| "Portopulmonary hypertension is a recognized but uncommon complication of cirrhosis." | ( Hou, MC; Lee, SD; Lin, HC; Wang, YW; Yang, YY, 2006) |
| "Pulmonary hypertension is a serious disorder, difficult to treat especially in the severe forms." | ( Azar, R; El, AB; Hamdan, R; Kassab, R; Salame, E, 2006) |
| "Pulmonary hypertension is associated with sudden death and is a risk factor for mortality in adult patients with sickle cell disease." | ( Barnett, C; Coles, WA; Ernst, I; Gladwin, MT; Hunter, LA; Kato, GJ; Macarthur, P; Machado, RF; Mack, AK; Martyr, S; Nichols, JP; Sachdev, V, 2007) |
| "Pulmonary hypertension is a highly prevalent complication of sickle cell disease and is a strong risk factor for early mortality." | ( Bivalacqua, TJ; Campbell-Lee, SA; Champion, HC; Cochard, AE; Diwan, BA; Gladwin, MT; Hsu, LL; Manci, EA; Noguchi, CT; Schechter, AN; Schimel, DM; Wang, X, 2007) |
| "Pulmonary hypertension is characterised by a progressive increase in pulmonary vascular resistance and a poor prognosis." | ( Leibovitch, L; Matok, I; Paret, G, 2007) |
| "Pulmonary hypertension is a common problem in patients with congenital diaphragmatic hernia (CDH)." | ( Friedlich, P; Garingo, A; Noori, S; Seri, I; Wong, P, 2007) |
| "Pulmonary hypertension is a common finding in patients with idiopathic pulmonary fibrosis (IPF), and is associated with increased morbidity and mortality." | ( Anstrom, KJ; Collard, HR; Schwarz, MI; Zisman, DA, 2007) |
| "Primary pulmonary hypertension is a rare disease with an ominous prognosis for which new therapeutic options are being developed." | ( Ozenci, M; Sayin, T, 2007) |
| "Portopulmonary hypertension is characterized by a chronic liver disease associated with a mean pulmonary artery pressure >25 mmHg at rest, an increased pulmonary vascular resistance and a capillary pulmonary pressure <15 mmHg with portal hypertension." | ( Rajaona, HR; Rajaonarivelo, P; Ramanampamonjy, RM; Razafimahefa, SH, 2007) |
| "Pulmonary hypertension is frequently observed in some cardiac malformation and in congenital diaphragmatic hernia, in meconium aspiration syndrome, neonatal sepsis, podalic presentation and male sex." | ( Camporesi, A; Silvani, P, 2007) |
| "Hypoxic pulmonary hypertension is usually only moderate and limited to medial hypertrophy with varying degrees of adventitial change, but may progress to extensive remodelling in some species." | ( Dewachter, L; Naeije, R, 2007) |
| "Pulmonary hypertension is a condition associated with a variety of pulmonary disorders whose common denominator is alveolar hypoxia." | ( Preston, IR, 2007) |
| "Pulmonary hypertension is common in idiopathic pulmonary fibrosis patients awaiting lung transplant, but the elevations in mean pulmonary arterial pressure are moderate." | ( Cors, CS; Lettieri, CJ; Nathan, SD; Shorr, AF; Wainright, JL, 2007) |
| "Pulmonary hypertension is a common complication of sickle cell disease (SCD) and a risk factor for early death." | ( Ackah, D; Castro, O; Chanock, SJ; Cobb, C; Gladwin, MT; Kato, GJ; Machado, R; Orr, N; Percy, MJ; Sachdev, V; Taylor, JG, 2008) |
| "Moderate degrees of pulmonary hypertension are most often the consequence of acute or chronic heart failure, hypoxemia, or acute pulmonary embolism, and may be relatively rapidly reversible." | ( Bayram, M; Hector-Word, Z; Rubenfire, M, 2007) |
| "Hypoxia-induced pulmonary hypertension is associated with an impairment of nitric oxide-mediated vasorelaxation in the pulmonary circulation that is not prevented by exercise training." | ( Dauzat, M; Goret, L; Guiraud, I; Obert, P; Tanguy, S, 2008) |
| "Steady-state mild pulmonary hypertension is a risk factor for death in adults with sickle cell disease." | ( Adnot, S; Brochard, L; Brun-Buisson, C; Galacteros, F; Godeau, B; Habibi, A; Leon, R; Maitre, B; Mekontso Dessap, A; Nzouakou, R; Roudot-Thoraval, F, 2008) |
| "Pulmonary hypertension is a relentlessly progressive disease leading to right heart failure and death." | ( Barnett, CF; Hsue, PY; Machado, RF, 2008) |
| "Pulmonary hypertension is common among Nigerian SCD patients." | ( Akpanpe, P; Aliyu, N; Aliyu, ZY; Attah, E; Babadoko, A; Gladwin, MT; Gordeuk, V; Kato, GJ; Mamman, AI; Mendelsohn, L; Sachdev, V; Suleiman, Y; Yusuf, J, 2008) |
| "Chronic hypoxic pulmonary hypertension is characterized by vasoconstriction and vascular remodeling and impaired endothelial nitric oxide (NO) production." | ( Demiryurek, AT; Gumusel, B; Turan, NN; Yildiz, G, 2008) |
| "Pulmonary hypertension is a kind of disease associated with a very high rate of mortality." | ( Chi, MG; Dong, JJ; Dong, SJ; Gong, ZH; Li, X; Liu, KL; Zheng, JQ, 2008) |
| "Mild-to-moderate pulmonary hypertension is a common complication of chronic obstructive pulmonary disease (COPD); such a complication is associated with increased risks of exacerbation and decreased survival." | ( Chaouat, A; Naeije, R; Weitzenblum, E, 2008) |
| "Pulmonary hypertension is a life-threatening disease, and alternative strategies are essential for patients with critical pulmonary hypertension." | ( Amano, S; Arai, Y; Chandra, BI; Hirose, K; Ikeda, T; Kimura, Y; Komeda, M; Kushibiki, T; Marui, A; Sakaguchi, H; Tabata, Y; Yuang, H, 2008) |
| "Pulmonary hypertension is characterized by abnormal vascular remodeling leading to occlusion of pulmonary arteries and increased stress placed on the right ventricle (RV)." | ( Broderick, TL; King, TM, 2008) |
| "In adults, pulmonary hypertension is significantly associated with mortality." | ( Bazzy-Asaad, A; Carbonella, J; Friedman, A; Pashankar, FD, 2009) |
| "Hypoxic pulmonary hypertension is an important pathophysiologic process of various cardiovascular diseases." | ( Du, JB; Jin, HF; Tang, CS; Tang, XY; Tian, Y, 2008) |
| "Primary pulmonary hypertension is a fatal disease that frequently becomes evident in pregnancy." | ( Ejima, Y; Kurosawa, S; Matsubara, M; Toyama, H; Wagatsuma, T, 2009) |
| "Pulmonary hypertension is an important complication of COPD." | ( Elliott, CG; Hegewald, MJ, 2009) |
| "However, if pulmonary hypertension is secondary to other causes such as congenital heart disease, it is possible to survive for 30 years or more without treatment." | ( Tulloh, R, 2009) |
| "Pulmonary hypertension is rare in chronic respiratory diseases but has a strong impact on the prognosis and is partly underlined by factors other than hypoxaemia." | ( Bonnette, P; Danel, C; Delclaux, C; Henno, P; Israël-Biet, D; Lévy, M; Maurey, C; Souilamas, R; Stern, M, 2009) |
| "Severe pulmonary hypertension is a lethal group of disorders which preferentially afflicts women." | ( Sweeney, L; Voelkel, NF, 2009) |
| "Pulmonary hypertension is an infrequent respiratory complication of this syndrome and might be associated with increased levels of various cytokines, chemokines and growth factors as part of the inflammatory phenomena that involve the physiopathology of POEMS syndrome." | ( Athanazio, RA; Dias, SA; Jardim, C; Rached, S; Souza, R, 2009) |
| "Pulmonary Hypertension is a serious complication of sickle cell disease (SCD), with high morbidity and mortality." | ( Coles, WA; Gladwin, MT; Kato, GJ; Machado, RF; Minniti, CP; Sachdev, V, 2009) |
| "Severe pulmonary hypertension is a progressive disease which leads to limitations of functional status and poor survival." | ( Dumija, Z; Jakopović, M; Knezević, A; Samarzija, M; Samija, M; Sever, B; Vidjak, V; Zuljević, E, 2009) |
| "Pulmonary hypertension is a group of diseases comprising vascular constriction and obstructive changes of the pulmonary vasculature." | ( Jiang, W; Jiang, Z; Li, B; Li, Y; Wang, C; Zeng, Z, 2010) |
| "Severe pulmonary hypertension is irreversible and often fatal." | ( Comhair, SA; Erzurum, SC; Fijalkowska, I; Janocha, AJ; Krishnamachary, B; Mao, T; Mavrakis, LA; Richter, A; Tuder, RM; Xu, W; Zhen, L, 2010) |
| "Pulmonary hypertension is highly prevalent in young sickle cell disease and thalassemia patients, where elevated serum ferritin and NT-pro-BNP are the main indicators." | ( Adly, AA; El Alfy, MS; Khairy, AT; Mokhtar, GM; Tawfik, LM, 2010) |
| "Pulmonary hypertension is a characteristic feature of acute respiratory distress syndrome (ARDS) and contributes to mortality." | ( Cornet, AD; Girbes, AR; Hofstra, JJ; Juffermans, NP; Swart, EL, 2010) |
| "Hypoxic pulmonary hypertension is a disease of the lung vasculature that is usually quantified by pulmonary vascular resistance (PVR)." | ( Chesler, NC; Naeije, R; Vanderpool, RR, 2010) |
| "Although pulmonary hypertension is associated with a risk of maternal mortality and most women are advised against pregnancy, new therapies may improve the outcome of pregnancy in patients with pulmonary hypertension." | ( Elkayam, U; Goland, S; Goodwin, TM; Habib, M; Janmohamed, M; Tsai, F, 2010) |
| "Pulmonary Hypertension is a severe lung disease, which is characterized by vasoconstriction and remodelling of the vessel wall." | ( Grimminger, F; Schermuly, RT, 2010) |
| "Pulmonary hypertension is associated with reduced nitric oxide bioavailability and early mortality in sickle cell disease (SCD)." | ( Gottliebson, W; Higashimoto, T; Kalra, VK; Kato, GJ; Malik, P; Mendelsohn, L; Nichols, WC; Pauciulo, MW; Sundaram, N; Tailor, A; Wang, X; Wansapura, J, 2010) |
| "Severe pulmonary hypertension is a debilitating disease with short life expectancy that often affects young people." | ( Singh, TP, 2010) |
| "Pulmonary hypertension is a kind of disease associated with a very high rate of mortality, and there are not many effective drugs for the treatment." | ( Chi, MG; Dong, HJ; Gong, ZH; Kong, LL; Liang, YJ; Liu, KL; Pan, XF; Yan, LD; Yong, Z; Zhang, C, 2010) |
| "Pulmonary hypertension is a known consequence of sickle cell anemia." | ( Akinsheye, I; Klings, ES, 2010) |
| "Therefore, pulmonary hypertension is a common feature of heart failure with preserved as well as reduced systolic function." | ( Guglin, M; Khan, H, 2010) |
| "Precapillary pulmonary hypertension is defined by an increase in mPAP > or =25 mmHg and a pulmonary capillary wedge pressure (PCWP)< or =15 mmHg associated with a normal or reduced cardiac output." | ( Chaouat, A; Montani, D, 2010) |
| "Pulmonary hypertension is a frequent complication of chronic obstructive pulmonary disease (COPD) and associated with a worse survival and increased risk of hospitalization for exacerbation of COPD." | ( Ban, HJ; Chi, SY; Kim, EY; Kim, KS; Kim, YC; Kwon, YS; Lim, SC; Oh, IJ; Shin, HJ; Yoon, BK, 2010) |
| "Pulmonary hypertension is common in advanced fibrotic IIP, and has a negative impact on survival." | ( Blumenthal, JP; Bresser, P; Jonkers, RE; Peek, N; Peelen, L; Prijs, M; van Steenwijk, RP; Wells, AU, 2010) |
| "Secondary pulmonary hypertension is a frequent condition after heart valve surgery." | ( Bulat, C; Carev, M; Husedzinović, I; Jercić, A; Karanović, N; Letica, D; Lojpur, M; Marovih, Z; Nenadić, D, 2010) |
| "Pulmonary hypertension is a severe progressive disease with a marked morbidity and a high mortality attributed to right heart failure." | ( Dwyer, N; Kilpatrick, D, 2011) |
| "Portopulmonary hypertension is a complication of chronic liver disease, which has significant effects on survival and prognosis." | ( Ahn, TH; Choi, IS; Chung, WJ; Kim, BR; Kim, EJ; Kim, MG; Oh, KY; Park, YM; Shin, EK; Shin, KC; Shin, MS, 2010) |
| "Neonatal pulmonary hypertension is characterized by hypoxia, abnormal vascular remodeling, and impaired alveolarization." | ( Dakshinamurti, S; Fediuk, J; Hinton, M; Nolette, N; Postolow, F, 2011) |
| "Pulmonary hypertension is characterized by increased vascular resistances, that could lead to right heart failure and death." | ( Beretta, L; Fumagalli, F; Latini, R; Masson, S; Santaniello, A; Scorza, R; Zambelli, V, 2011) |
| "Pulmonary hypertension is associated with vascular remodeling and increased extracellular matrix (ECM) deposition." | ( Cao, YN; Myers, AC; Paudel, O; Sham, JS; Umesh, A, 2011) |
| "Pulmonary hypertension is a frequent cause of morbidity and mortality in patients with systemic sclerosis." | ( Farber, HW; York, M, 2011) |
| "Pulmonary hypertension is a rare disease in neonates, infants, and children, and is associated with substantial morbidity and mortality." | ( Datar, SA; Fineman, JR; Oishi, P, 2011) |
| "APE-induced pulmonary hypertension is aggravated by active pulmonary vasoconstriction." | ( Dias, CA; Montenegro, MF; Neto-Neves, EM; Tanus-Santos, JE, 2012) |
| "Pulmonary hypertension is a severe and progressive disease, a key feature of which is pulmonary vascular remodeling." | ( Caldwell, RW; Greer, PA; Han, W; Ma, W; Su, Y; Toque, HA; Tuder, RM; Wang, KK, 2011) |
| "Pulmonary hypertension is associated with significant morbidity and mortality." | ( Alehan, D; Karagöz, T; Ozer, S; Ozkutlu, S; Sahin, M; Yıldırım, I, 2012) |
| "Pulmonary hypertension is induced in experimental animals by subjecting them to chronic hypoxic conditions." | ( Devadasu, VR; Ravi Kumar, MN; Wadsworth, RM, 2012) |
| "Hypoxic pulmonary hypertension is a worldwide public health problem." | ( Carlin, CM; Celnik, DF; Pak, O; Peacock, AJ; Wadsworth, R; Welsh, DJ, 2012) |
| "Development of pulmonary hypertension is a common and deadly complication of interstitial lung disease." | ( Acero, L; Belardinelli, L; Blackburn, MR; Blackwell, TS; Eltzschig, HK; Grenz, A; Hemnes, A; Johnston, RA; Karmouty-Quintana, H; Melicoff, E; Weng, T; West, JD; Xia, Y; Zeng, D; Zhong, H, 2012) |
| "Pulmonary hypertension is a rare but potentially fatal complication of ibuprofen administration in preterm infants." | ( Aghai, ZH; Amendolia, B; Bhat, V; Lynn, M; Ritz, SB, 2012) |
| "The development of pulmonary hypertension is a common accompaniment of congenital heart disease (CHD) with increased pulmonary blood flow." | ( Aramburo, A; Black, SM; Fineman, JR; Kalkan, G; Kallarackal, S; Kumar, S; Rafikov, R; Rehmani, I; Sharma, S; Sun, X; Tian, J, 2012) |
| "Pulmonary hypertension is becoming a recognized complication of the hereditary and acquired haemolytic anaemias, associated with a poor prognosis." | ( Hill, A; Hillmen, P; Kelly, R; Khurisgara, G; Richards, SJ; Sapsford, RJ; Scally, A; Sivananthan, MU, 2012) |
| "Pulmonary hypertension is a devastating disorder without any available treatment strategies that satisfactorily promote the survival of patients." | ( Bansal, G; Marcocci, L; Pavlickova, L; Suzuki, YJ; Wong, CM, 2013) |
| "Hypoxic pulmonary hypertension is a life-threatening emergency if untreated." | ( Hu, N; Jiang, XX; Li, B; Li, J; Miao, Q; Miao, S; Shi, XP; Wang, SW; Ye, MX; Zhang, J; Zhang, S, 2012) |
| "Pulmonary hypertension is associated with a worse prognosis after cardiac transplantation." | ( Bacal, F; Bocchi, EA; Fiorelli, AI; Freitas, AF; Mangini, S; Moreira, LF; Oliveira Júnior, Jde L; Santos, RH; Silva, CP; Tsutsui, JM, 2012) |
| "Pulmonary hypertension is a complex, progressive condition arising from a variety of genetic and pathogenic causes." | ( Laurie, SS; Shimoda, LA, 2013) |
| "Pulmonary hypertension is a serious complication of chronic obstructive pulmonary disease (COPD) that currently has no established pharmacological treatment." | ( Barberà, JA; Blanco, I; Gea, J; Gimeno-Santos, E; Gómez, B; Güell, R; Roca, J; Rodriguez, DA; Santos, S; Torres, F; Vilaró, J, 2013) |
| "Pulmonary hypertension is a common but often overlooked complication associated with thalassemia syndromes." | ( Kim, HY; Klings, ES; Kuypers, FA; Kwiatkowski, JL; Larkin, S; Morris, CR; Neufeld, EJ; Olivieri, NF; Porter, JB; Sachdev, V; Singer, ST; Suh, JH; Sweeters, N; Taher, A; Thompson, AA; Trachtenberg, FL; Vichinsky, EP; Virzi, L; Wood, J, 2013) |
| "Pulmonary hypertension is defined by 25 mmHg pressure at rest, and 35 mmHg pressure at exercise, in the pulmonary arteries." | ( Brachmann, J; Friedel, N; Hohenforst-Schmidt, W; Hornig, J; Zarogoulidis, K; Zarogoulidis, P, 2013) |
| "Pulmonary hypertension is commonly encountered in advanced lung diseases such as CF." | ( Tonelli, AR, 2013) |
| "Pulmonary hypertension is common in patients with CF and it occurs largely because of hypoxemia." | ( Tonelli, AR, 2013) |
| "Pulmonary hypertension is a progressive disease characterized by marked pulmonary arterial remodeling and increased vascular resistance." | ( Dong, H; Dong, M; Li, Y; Li, Z; Liu, M; Liu, Y; Luo, Y; Niu, W; Sun, R; Wang, Y; Xu, D; Zhang, B; Zhao, P, 2014) |
| "Pulmonary hypertension is associated with higher mortality rates." | ( Arrigain, S; Dweik, RA; Gaur, V; Heresi, GA; Minai, OA; Nally, JV; Navaneethan, SD; Rahman, M; Schold, JD; Wehbe, E, 2014) |
| "Pulmonary hypertension is common in bronchopulmonary dysplasia and is associated with increased mortality and morbidity." | ( Ambalavanan, N; Mourani, P, 2014) |
| "Pulmonary hypertension is a progressive disease of diverse origin with devastating consequences in adults as well as in children." | ( Burhenne, J; Carls, A; Enderle, Y; Gorenflo, M; Haefeli, WE; Winter, J, 2014) |
| "Pulmonary hypertension is a progressive disease of various origins that is associated with right ventricular dysfunction." | ( Agha, AM; Ahmed, LA; Obaid, AA; Zaki, HF, 2014) |
| "Pulmonary hypertension is a life-threatening medical condition, and a growing body of evidence shows that the expression of connective tissue growth factor (CTGF) is significantly associated with its pathogenesis, making it an attractive therapeutic target." | ( Fei, LM; Sun, GY; Wang, R; Xu, R; Zeng, DS; Zhang, Y; Zhou, SJ; Zhu, QQ, 2014) |
| "Pulmonary hypertension is frequent in advanced chronic respiratory diseases, with an estimated prevalence at the time of pulmonary transplantation of 30-50 % in idiopathic pulmonary fibrosis, 30-50 % in chronic obstructive pulmonary disease, 50 % in combined pulmonary fibrosis and emphysema, 75 % in sarcoidosis, and more than 75 % of cases in pulmonary Langerhans cell histiocytosis." | ( Cottin, V, 2014) |
| "Early detection in pulmonary hypertension is the best way to improve the survival in these diseases." | ( Legendre, P; Mouthon, L, 2014) |
| "Patients with pulmonary hypertension are some of the most challenging for an anaesthesiologist to manage." | ( Rabanal, JM; Real, MI; Williams, M, 2014) |
| "Pulmonary hypertension is a condition characterized by vasoconstriction, vascular cell proliferation, inflammation, microthrombosis, and vessel wall remodelation." | ( Kruzliak, P; Maruyama, J; Maruyama, K, 2014) |
| "Pulmonary hypertension is a disease with severe consequences for the human body." | ( Hohenforst-Schmidt, W; Huang, H; Kakolyris, S; Kioumis, I; Lampaki, S; Li, Q; Organtzis, J; Papaiwannou, A; Petridis, D; Pitsiou, G; Porpodis, K; Syrigos, K; Tsiouda, T; Turner, JF; Zarogoulidis, K; Zarogoulidis, P, 2014) |
| "Severe pulmonary hypertension is a debilitating disease with an alarmingly low 5-yr life expectancy." | ( Chettimada, S; Gebb, SA; Gupte, R; Gupte, SA; McMurtry, IF; Rawat, D, 2015) |
| "The management of pulmonary hypertension is multi-faceted, with therapies directed at supporting cardiovascular and pulmonary function, treating the underlying cause (if feasible), and preventing irreversible remodeling of the pulmonary vasculature." | ( Pandya, KA; Puligandla, PS, 2015) |
| "Pulmonary hypertension is associated with mortality." | ( Özçelik, N; Özsu, S, 2015) |
| "Pulmonary hypertension is associated with poor outcome in patients with chronic heart failure (CHF) and may be a therapeutic target." | ( Ciobanu, A; Clark, AL; Cleland, JG; Damy, T; Dubois-Randé, JL; Guellich, A; Hittinger, L; Hobkirk, J; Kallvikbacka-Bennett, A; Rigby, AS; Walters, M, 2015) |
| "Pulmonary hypertension is a fatal disease characterized by a progressive increase in pulmonary artery pressure accompanied by pulmonary vascular remodeling and increased vasomotor tone." | ( Raj, JU; Ramchandran, R; Sun, M; Yang, Q, 2015) |
| "Pulmonary hypertension is a major cardiac complication in non-transfusion-dependent thalassemia (NTDT)." | ( Charoenkwan, P; Chattipakorn, N; Choeyprasert, W; Inthawong, K; Natesirinilkul, R; Phrommintikul, A; Sanguansermsri, T; Silvilairat, S; Siwasomboon, C; Srichairatanakool, S; Tantiworawit, A; Visrutaratna, P, 2015) |
| "• Pulmonary hypertension is a life-threatening disease." | ( Kraemer, US; Ten Kate, CA; Tibboel, D, 2015) |
| "Secondary pulmonary hypertension is common in heart failure (HF) patients." | ( Johnson, BD; Joyner, MJ; Olson, TP; Snyder, EM; Van Iterson, EH, 2015) |
| "Pulmonary hypertension is a common finding in HD patients and a valuable predictor of mortality and cardiovascular events." | ( Abad, S; López-Gómez, JM; Panizo, N; Quiroga, B; Reque, J; Ruiz, C; Vega, A; Villaverde, MT, 2016) |
| "Pulmonary hypertension is a disease with diverse etiology." | ( Kornacewicz-Jach, Z; Peregud-Pogorzelska, M, 2015) |
| "Pulmonary hypertension is associated with diverse cardiac, pulmonary, and systemic diseases in neonates, infants, and older children and contributes to significant morbidity and mortality." | ( Abman, SH; Adatia, I; Archer, SL; Barst, RJ; Chung, WK; Cornfield, D; Deterding, R; Earing, M; Feinstein, JA; Fineman, JR; Friedberg, MK; Hanna, BD; Hansmann, G; Humpl, T; Ivy, DD; Keller, RL; Kinsella, JP; Kuehne, T; Kulik, T; Mallory, G; Mullen, M; Raj, JU; Rosenzweig, EB; Steinhorn, R; Stenmark, KR; Thébaud, B; Wessel, DL, 2015) |
| "Pulmonary hypertension is a well recognised complication of chronic hypoxic lung diseases, which are among the most common causes of death and disability worldwide." | ( Gaine, S; Keane, MP; McLoughlin, P; Rowan, SC, 2016) |
| "Pulmonary hypertension is a progressive disease with poor prognosis, characterized by pathological inward remodelling and loss of patency of the lung vasculature." | ( Böhm, M; Dahal, BK; Elgheznawy, A; Fisslthaler, B; Fleming, I; Ghofrani, HA; Gödecke, A; Jungmann, A; Katus, HA; Kojonazarov, B; Müller, OJ; Popp, R; Pullamsetti, SS; Schermuly, RT; Seeger, W; Shi, L, 2016) |
| "Pulmonary hypertension is a rare disorder that, without treatment, is progressive and fatal within 3-4 years." | ( Bartow, MJ; Bourgeois, CR; Chan, RA; Edward, JA; Giles, TD; Kadowitz, PJ; Murthy, SN; Pankey, EA; Peak, TA; Prieto, MC; Song, BM; Swan, KW; Yoo, D, 2016) |
| "Pulmonary hypertension is a condition of complex aetiology that culminates in right heart failure and early death." | ( Gibbs, JS; Seager, MJ; Tulloh, RM; Wardle, AJ; Wardle, R, 2016) |
| "Progression of pulmonary hypertension is associated with the activation of the NNMT-MNA pathway in rats and humans." | ( Chlopicki, S; Fedorowicz, A; Jakubowski, A; Kopec, G; Kutryb-Zając, B; Mateuszuk, Ł; Skórka, T; Słomińska, E; Walczak, M; Zakrzewska, A; Łomnicka, M, 2016) |
| "Pulmonary hypertension is a fatal disease; however, its pathogenesis still remains to be elucidated." | ( Al-Mamun, E; Kikuchi, N; Kurosawa, R; Miyata, S; Morser, J; Nogi, M; Numano, K; Omura, J; Satoh, K; Satoh, T; Shimokawa, H; Siddique, MA; Sunamura, S; Suzuki, K; Yaoita, N, 2017) |
| "Pulmonary hypertension is a life-threatening condition that affects people of all ages that can occur as an idiopathic disorder at birth or as part of a variety of cardiovascular and infectious disorders." | ( Davis, MD; Donn, SM; Ward, RM, 2017) |
| "Pulmonary hypertension is still not curable and the available current therapies can only alleviate symptoms without hindering the progression of disease." | ( Ahmed, LA; El-Maraghy, SA; Rizk, SM, 2017) |
| "Pulmonary hypertension is defined by a mean pulmonary artery pressure ≥25 mm Hg at rest." | ( Honorato Pérez, J, 2017) |
| "Pulmonary hypertension is characterized by pulmonary endothelial dysfunction." | ( Alvarez, RA; Bachman, T; Bauer, E; Galley, JC; Goncharov, D; Goncharova, E; Hahn, SA; Hu, J; Miller, MP; Mora, AL; Rojas, M; Sembrat, J; Straub, AC, 2017) |
| "Pulmonary hypertension is a life-threatening complication in β-thalassemia." | ( Chuncharunee, S; Paiboonsukwong, K; Pienvichit, P; Rakyhao, T; Sathavorasmith, P; Sibmooh, N; Sirirat, K; Srihirun, S; Sritara, P; Sriwantana, T; Yingchoncharoen, T, 2018) |
| "Hypoxic pulmonary hypertension is characterized by the remodeling of pulmonary artery." | ( Dong, M; Li, Y; Luo, Y; Zhang, N; Zhao, F, 2018) |
| "Pulmonary hypertension is a severe, incurable disease with a poor prognosis." | ( Breuer, J; Knies, R; Lorenz, K; Matthey, M; Neumann, V; Seidinger, A; Simon, A; Wenzel, D, 2018) |
| "Pulmonary hypertension is associated with endothelial dysfunction resulting in the suppression of magnesium modulation of vasodilatation." | ( Huang, QH; Lin, MJ; Mu, YP; Sham, JSK; Yan, FR; Zheng, SY; Zhu, JL; Zhuang, XL, 2018) |
| "Pulmonary hypertension is a rapidly progressive, life-threatening, and often fatal disease." | ( Bueno-Beti, C; Hadri, L; Hajjar, RJ; Sassi, Y, 2018) |
| "Pulmonary hypertension is a co-morbidity, which strongly participates in morbi-mortality in patients with chronic obstructive pulmonary disease (COPD)." | ( Chabert, C; Dubouchaud, H; Furze, R; Khochbin, S; Pison, C; Prinjha, RK; Rousseaux, S; Schlattner, U; Smithers, N; Veyrenc, S, 2018) |
| "Portopulmonary hypertension is a form of pulmo- nary hypertension associated with portal hypertension with/without liver cirrhosis." | ( Fujino, Y; Ihara, T; Iwasaki, M; Kamibayashi, T, 2016) |
| "Pulmonary hypertension is frequently associated with right ventricular dysfunction and progressive right ventricular failure, and an increased prevalence of sleep apnea has been described." | ( Carvalho, CG; Granton, J; Ryan, CM; Yadollahi, A, 2019) |
| "Given that pulmonary hypertension is strongly associated with environmental exposure, we hypothesize that CYPs play a role in the development and maintenance of pathological vascular remodeling." | ( Gomez-Arroyo, J; Johansen, AKZ; Kwapiszewska, G; Voelkel, NF, 2019) |
| "Pulmonary hypertension is frequently combined with PCH when capillary proliferation invades to nearby pulmonary vascular systems." | ( Chung, WB; Han, D; Jang, W; Jung, JI; Kang, JY; Kim, M; Kim, TJ; Lee, J; Lee, KY; Yeo, CD, 2019) |
| "Pulmonary hypertension is a common complication of bronchopulmonary dysplasia, with a high mortality rate." | ( Bachiller Carnicero, L; Corredera Sánchez, A; Del Cerro Marín, MJ; Martínez Orgado, JA; Puente Ubierna, N, 2019) |
| "Pulmonary hypertension is one of the most challenging complications in congenital heart surgery." | ( Bronicki, RA; Evey, L; Flores, S; Loomba, RS; Wong, J, 2019) |
| "Pulmonary hypertension is a significant complication for some patients with COVID-19 pneumonia, especially those requiring intensive care." | ( Couper, J; MacKenzie, K; Peña, AS; Shaw, G; Wiltshire, E, 2020) |
| "Pulmonary hypertension is a complex disorder characterized by pulmonary vascular remodeling and right ventricular hypertrophy, leading to right heart failure." | ( Abdul-Salam, VB; Alvarez-Laviada, A; Dries, E; Faggian, G; Gorelik, J; Medvedev, R; Miragoli, M; Rossi, S; Sanchez-Alonso, JL; Schorn, T; Trayanova, N; Wojciak-Stothard, B, 2021) |
| "Polycythemia and pulmonary hypertension are 2 human diseases for which better therapies are needed." | ( Ghosh, MC; Linehan, WM; Noguchi, A; Ollivierre, WH; Rouault, TA; Springer, DA; Zhang, DL, 2021) |
| "Pulmonary hypertension is a rare and complex disease with poor prognosis." | ( Lafuente-Romero, A; Rodriguez Ogando, A, 2021) |
| "Hypoxic pulmonary hypertension is a particularly serious and maladaptive response to chronic hypoxia, which results from vasoconstriction and pathological remodeling of pulmonary arteries, and can lead to pulmonary edema and right ventricle hypertrophy." | ( Rhem, RG; Scott, GR; Wearing, OH; West, CM, 2021) |
| "Pulmonary hypertension is characterized by vasoconstriction and remodeling of pulmonary arteries, leading to right ventricular hypertrophy and failure." | ( Aalling, M; Andersen, CU; Markvardsen, LK; Mogensen, S; Pinilla, E; Prat-Duran, J; Simonsen, U; Sønderskov, LD; Wandall-Frostholm, C, 2021) |
| "Drug therapy for pulmonary hypertension is recommended only for those patients who have irreversible pulmonary hypertension." | ( Abdrakhmanova, Z; Bekenov, N; Bektenova, G; Datkayeva, G; Gatauova, M; Ilyassova, G; Kemelbekov, K; Khatamov, F; Kuandykov, Y; Musaev, Y; Omarova, B; Tasbulatov, N; Tazhiyeva, A; Tuktibayeva, S; Zhumabekov, Z, 2021) |
| "Pulmonary hypertension is one of the most common diseases among older people." | ( Amin, F; Jamialahmadi, T; Johnston, TP; Sahebkar, A; Yousefvand, S, 2021) |
| "• The diagnosis pulmonary hypertension is complex, especially in infants born after severe early-onset fetal growth restriction." | ( Berger, RMF; Ganzevoort, W; Gordijn, SJ; Limpens, J; Lopriore, E; Onland, W; Pels, A; Reiss, IKM; van Heijst, AFJ, 2022) |
| "Pulmonary hypertension is a significant complication in thalassemia patients." | ( Chuncharunee, S; Pienvichit, P; Pussadhamma, B; Sasiprapha, T; Sibmooh, N; Sriwantana, T; Yingchoncharoen, T, 2022) |
| "Pulmonary hypertension is defined by a mean pulmonary artery pressure greater than 20 mm Hg and is classified into 5 clinical groups based on etiology, pathophysiology, and treatment." | ( Cockrill, BA; Ruopp, NF, 2022) |
| "Pulmonary hypertension is a lethal disease characterized by pulmonary vascular remodeling and is mediated by abnormal proliferation and migration of pulmonary arterial smooth muscle cells (PASMCs)." | ( Gou, D; Huang, X; Kang, K; Li, L; Linneman, J; Luo, Y; Niu, Y; Wang, J; Xia, Q; Xia, S; Xu, J; Yang, L; Yin, H; Zhong, Y, 2022) |
| "Pulmonary hypertension is a group of disorders characterized by elevated mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance." | ( Chalupský, K; D Uris Ova, J; Hampl, V; Kaftanová, B; Krása, K; Miková, D; Minaříkova, M; Srbová, M; Vajnerova, O, 2022) |
| "Pulmonary hypertension is a group of disorders characterized by elevated mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance." | ( Chalupský, K; D Uris Ova, J; Hampl, V; Kaftanová, B; Krása, K; Miková, D; Minaříkova, M; Srbová, M; Vajnerova, O, 2022) |
| "Pulmonary hypertension is a group of disorders characterized by elevated mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance." | ( Chalupský, K; D Uris Ova, J; Hampl, V; Kaftanová, B; Krása, K; Miková, D; Minaříkova, M; Srbová, M; Vajnerova, O, 2022) |
| "Pulmonary hypertension is a common complication of COPD." | ( Huang, H; Yang, L, 2023) |
| Excerpt | Reference |
|---|
| "The value of vasodilatatory treatment of pulmonary hypertension due to chronic obturative pulmonary disease (c." | ( Lewczuk, J; Palka, PS; Piszko, P; Porada, A; Sobkowicz-Woźniak, B; Spikowski, J; Szczygielski, J; Trzesicka, M; Wrabec, K, 1990) |
| "Development of effective treatment for human pulmonary hypertension (PHT) has been hampered by an incomplete understanding of its pathogenesis." | ( Hyers, TM; Lagunoff, D; Ohar, JA; Pyle, JA; Waller, KS; Webster, RO, 1990) |
| "Drug treatment for pulmonary hypertension and cor pulmonale may improve prognosis and prolong life." | ( Goldstein, RA, 1985) |
| "Symptomatic treatment of pulmonary hypertension aims at reducing right ventricular afterload in order to delay the development of ventricular failure." | ( Dubiel, JP, 1989) |
| "Nitroglycerin was used to treat systemic or pulmonary hypertension, myocardial ischaemia and ventricular failure." | ( Bessette, MC; Cohen, AY; Townsend, GE; Whalley, DG; Wynands, JE, 1983) |
| "The use of diazoxide in the treatment of pulmonary hypertension has been advocated recently." | ( Buch, J; Wennevold, A, 1981) |
| "PGE1 may be useful for the treatment of pulmonary hypertension in humans." | ( Ashino, Y; Fujimura, S; Hoshikawa, Y; Maeda, S; Noda, M; Ono, S; Song, C; Tabata, T; Tanita, T; Ueda, S, 1995) |
| "Monocrotaline-treated rats showed pulmonary hypertension with medial hypertrophy and perivascular fibrosis of pulmonary arteries." | ( Honda, M; Ishinaga, Y; Kuramochi, T; Maeda, A; Mansoor, AM; Mitsui, Y; Saida, K; Takabatake, T, 1995) |
| "IL-1ra treatment reduced pulmonary hypertension and right heart hypertrophy in the MCT model, but not in the chronic hypoxia model." | ( Arend, WP; Bridges, J; Tuder, RM; Voelkel, NF, 1994) |
| "In MCT-treated rats, pulmonary hypertension, right ventricular hypertrophy, and pulmonary vascular thickening developed at 3 weeks after injection." | ( Ashino, Y; Fujimura, S; Hoshikawa, Y; Nishimura, T; Noda, M; Ono, S; Tabata, S; Tanita, T; Ueda, S, 1994) |
| "Therefore, the medical treatment of pulmonary hypertension is justified." | ( Fraisse, P; Kessler, R; Oswald, M; Weitzenblum, E, 1994) |
| "Nitric oxide may be useful in the treatment of pulmonary hypertension and the impaired gas exchange that occurs after lung transplantation." | ( Adatia, I; Arnold, JH; Fackler, JC; Lillehei, C; Palazzo, R; Thompson, JE; Wessel, DL, 1994) |
| "The role of nifedipine in the treatment of pulmonary hypertension secondary to chronic bronchitis may be limited because of its deleterious effect on venous admixture." | ( Bone, MF; Kalra, L, 1993) |
| "Consequently the treatment of pulmonary hypertension is justified in COPD." | ( Adnot, S; Samoyeau, R; Weitzenblum, E, 1995) |
| "Thus, NO inhalation is effective in the treatment of pulmonary hypertension and in the prevention of pulmonary hypertensive crises after total correction for congenital heart anomalies." | ( Haruna, M; Hayashi, H; Kamiya, T; Kumon, K; Matsui, J; Takamoto, S; Tanigami, H; Watanabe, Y; Yagihara, T; Yahagi, N, 1997) |
| "The combination of NO and PGE1 for the treatment of pulmonary hypertension should be considered for clinical application in situations where a combination of pulmonary hypertension and decreased left ventricular function is present." | ( Bund, M; Giess, W; Hartrumpf, M; Haverich, A; Krieg, P; Rohde, R; Wahlers, T, 1998) |
| "Nondrug treatments for pulmonary hypertension include (i) supplemental oxygen (> or = 15 h/day), which is the primary therapy in patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease and (ii) heart-lung or lung transplantation, which nowadays is regarded as a last resort." | ( Jeffery, TK; Wanstall, JC, 1998) |
| "Despite treatment, pulmonary hypertension progressively developed and responded to oxygen therapy." | ( Duvaltier, I; Labrune, P; Marquet, J; Niaudet, P; Odièvre, M; Trioche, P; Zittoun, J, 1999) |
| "vasodilators for treatment of pulmonary hypertension (PH) after cardiac surgery, but iNO is a potentially toxic gas, and patient subsets who benefit from iNO are not yet clearly defined." | ( Bürki, C; Engel, MH; Schmid, ER; Schmidlin, D; Seifert, B; Tornic, M, 1999) |
| "The major treatment of pulmonary hypertension is supplemental oxygen, but drugs such as calcium channel blockers may also be required." | ( Abman, SH, 2002) |
| "We review alternatives to conventional treatments for pulmonary hypertension with special reference to pediatrics." | ( Expósito Montes, JF; García Martínez, E; Ibarra de la Rosa, I; Pérez Navero, JL; Suárez de Lezo y Cruz Conde, J; Tejero Mateo, I, 2003) |
| "The fasudil treatment improved pulmonary hypertension, right ventricular hypertrophy, and pulmonary vascular lesions with suppression of VSMC proliferation and macrophage infiltration, enhanced VSMC apoptosis, and amelioration of endothelial dysfunction and VSMC hypercontraction." | ( Abe, K; Hattori, T; Kaibuchi, K; Matsumoto, Y; Morikawa, K; Nakashima, Y; Oi, K; Shimokawa, H; Sueishi, K; Takeshit, A; Uwatoku, T, 2004) |
| "In the absence of adequate treatment, primary pulmonary hypertension has a grave prognosis, with a median survival of 2." | ( Poon, M; Sulica, R, 2004) |
| "Use of inhaled nitric oxide for treatment of pulmonary hypertension in adult critical illness is limited by its mode of delivery and high costs, prompting evaluation of alternative therapies." | ( Bellingan, GJ; Finney, SJ; Glynne, PA; Ng, J; Shulman, R; Singer, M, 2005) |
| "There may be a case for pharmacologic treatment of pulmonary hypertension in selected patients with advanced COPD and right heart failure." | ( Naeije, R, 2005) |
| "Sildenafil offers potential to treat patients with pulmonary hypertension by selectively inhibiting phosphodiesterase type five pathways in the lung." | ( Allenby, M; Loke, TK; Madden, BP; Sheth, A, 2006) |
| "We report a case of successful treatment of pulmonary hypertension in a patient with beta-thalassemia major and review the literature on pulmonary hypertension and beta-thalassemia major." | ( Farber, HW; Tam, DH, 2006) |
| "Despite treatment for pulmonary hypertension and provision of respiratory support, the patient died." | ( Alioglu, B; Demirhan, B; Erbay, A; Ozbek, N; Ozyurek, E; Varan, B, 2006) |
| "For the treatment of pulmonary hypertension in children with congenital cardiac defects, a 0." | ( Danton, MD; MacArthur, KJ; Pollock, JC; Raja, SG, 2007) |
| "Although prostaglandin I2 is used to treat pulmonary hypertension (PH), continuous intravenous administration is necessary." | ( Fukuda, K; Ieda, M; Ieda, Y; Kanazawa, H; Kawakami, T; Kimura, K; Mochizuki, H; Ogawa, S; Satoh, T; Shimada, T; Tanabe, T; Yokoyama, C, 2007) |
| "Iloprost is effective for the treatment of pulmonary hypertension." | ( Banat, GA; Butrous, G; Dony, E; Ghofrani, HA; Grimminger, F; Lai, YJ; Pullamsetti, SS; Schermuly, RT; Seeger, W; Weissmann, N, 2008) |
| "Levosimendan can be used to treat pulmonary hypertension during operations for heart valve disease." | ( Cicekcioglu, F; Ersoy, O; Hijazi, A; Katircioglu, SF; Parlar, AI; Yay, K, 2008) |
| "Bosentan for the treatment of pulmonary hypertension was safe as well as effective in this patient with end-stage renal disease and hemodialysis." | ( Konishi, K; Kuriyama, T; Maruoka, M; Nakamura, M; Shigeta, A; Shinohara, M; Tada, Y; Takiguchi, Y; Tanabe, N; Tatsumi, K; Toyama, S; Yasuda, T, 2009) |
| "Treprostinil is labeled for treatment of pulmonary hypertension with New York Heart Association (NYHA) Class II, III and IV symptoms." | ( Hanna, BD; Walsh, M, 2009) |
| "In spite of recent advancements in the treatment of pulmonary hypertension, successful control has yet to be accomplished." | ( Bradford, CN; Ferreira, AJ; Francis, J; Hong, KH; Katovich, MJ; Oh, SP; Raizada, MK; Shenoy, V; Sriramula, S; Yamazato, M; Yamazato, Y; Yuan, L, 2009) |
| "Sildenafil is used to treat pulmonary hypertension in neonatal and pediatric patients." | ( Ahsman, MJ; Mathot, RA; Tibboel, D; van der Nagel, BC; Witjes, BC, 2010) |
| "Limited data exist for the treatment of pulmonary hypertension associated with idiopathic pulmonary fibrosis." | ( Ardehali, A; Belperio, JA; Fishbein, MC; Lynch, JP; Ross, DJ; Saggar, R; Shapiro, SS; Weigt, SS; Zisman, DA, 2009) |
| "The current treatment for pulmonary hypertension is limited and only provides symptomatic relief due to unknown cause and pathogenesis of the disease." | ( Crosswhite, P; Sun, Z, 2010) |
| "Drugs used to treat pulmonary hypertension may have detrimental effects on portal hypertension." | ( Abraldes, JG; Barberà, JA; Blanco, I; Bosch, J; Escribano, P; García-Pagan, JC; Melgosa, MT; Ricci, GL; Roca, J, 2010) |
| "In the treatment of pulmonary hypertension, this pathway is exogenously activated using inhaled NO or other pharmacological agents." | ( Aggarwal, S; Black, SM; Datar, S; Fineman, JR; Fratz, S; Gross, CM; Kalkan, G; Kumar, S; Oishi, P; Schreiber, C, 2011) |
| "We tried L-arginine for the treatment of pulmonary hypertension secondary to pulmonary embolism." | ( Edo, K; Ishibashi, T; Ishikawa, K; Maruyama, Y; Ogata, H; Takahashi, T; Watanabe, M, 2010) |
| "To observe simvastatin treatment of pulmonary hypertension in patients with coal workers pneumoconiosis (CWP)." | ( Li, DH; Mao, H; Wang, CJ; Zhang, SS, 2011) |
| "The findings may have potential for the treatment of pulmonary hypertension using PTEN as a target." | ( Citro, L; Khan, M; Kuppusamy, P; Meduru, S; Naidu, S; Ravi, Y; Rivera, BK; Sai-Sudhakar, CB; Selvendiran, K, 2013) |
| "Oral drugs have made the treatment of pulmonary hypertension (PH) feasible in non-expert centers, which could delay patient access to prostanoid therapy." | ( Badagliacca, R; Fedele, F; Ferrante, F; Iacoboni, C; Mancone, M; Marcon, S; Papa, S; Parola, D; Pezzuto, B; Poscia, R; Sardella, G; Valli, G; Vizza, CD, 2012) |
| "Inhaled nitric oxide (iNO) is used to treat pulmonary hypertension and is being investigated for prevention of bronchopulmonary dysplasia in neonates." | ( Auten, RL; Brahmajothi, MV; McMahon, TJ; Tinch, BT; Torok, JA; Zhu, H, 2012) |
| "Medications to treat pulmonary hypertension have focused on pulmonary vasodilatation." | ( Rich, S, 2012) |
| "The drugs that are currently used to treat pulmonary hypertension (PH) lack the ability to inhibit or reverse the pulmonary vascular remodeling that occurs during the course of the disease." | ( Jiang, L; Liu, H; Zhou, T, 2012) |
| "Sildenafil is used to treat pulmonary hypertension (PAH) in infants with congenital diaphragmatic hernia (CDH)." | ( Behrsin, J; Cheung, M; Patel, N, 2013) |
| "Therefore, treatment of pulmonary hypertension after surgery may be the most important issue affecting the prognosis." | ( Cingoz, F; Kurkluoglu, M; Sahin, MA; Tavlasoglu, M, 2013) |
| "Preemptive treatment of pulmonary hypertension with a combination of inhaled prostacyclin and milrinone before CPB was associated with a reduction in the severity of pulmonary hypertension." | ( Carrier, M; Denault, AY; Elmi-Sarabi, M; Fortier, A; Laflamme, M; Perrault, LP, 2015) |
| "However, the role of baicalin in the treatment of pulmonary hypertension remains unknown." | ( Cai, X; Chen, A; Chen, M; Huang, X; Liu, P; Wang, L; Xu, X; Yan, S; Yao, D, 2015) |
| "There is no recommendation for treating pulmonary hypertension (PH) when associated with chronic obstructive pulmonary disease (COPD)." | ( Chabanne, C; Cordier, JF; Cottin, V; Delaval, P; Girard, A; Jouneau, S; Khouatra, C; Lannes, M; Traclet, J; Turquier, S, 2015) |
| "Sildenafil may have a role in treatment of severe pulmonary hypertension after ibuprofen treatment for ductal closure." | ( Aleo, E; Arruza, L; Rodriguez-Castano, MJ, 2016) |
| "Using NO inhalation to treat neonatal pulmonary hypertension can significantly improve oxygen supply, reduce pulmonary artery pressure, shorten treatment time, and reduce mortality." | ( Li, ZG; Liang, HY; Liu, G; Lu, GZ; Wu, HW, 2016) |
| "Sildenafil used for treatment of pulmonary hypertension has potential for reducing mortality and improving oxygenation in neonates, especially in resource-limited settings where iNO is not available." | ( Kelly, LE; Ohlsson, A; Shah, PS, 2017) |
| "There are no approved treatments for pulmonary hypertension associated with idiopathic interstitial pneumonia (PH-IIP)." | ( Behr, J; Boateng, F; Collard, HR; Corte, TJ; Cottin, V; Hoeper, MM; Keogh, AM; Leuchte, H; Martinez, FJ; Mogulkoc, N; Nathan, SD; Ulrich, S; Wells, AU; Wuyts, WA; Yao, Z, 2019) |
| "However, the efficacy of TMP in the treatment of pulmonary hypertension (PH) is unknown." | ( Chen, Y; He, W; Hong, C; Liu, C; Lu, W; Ouyang, H; Wang, J; Wang, T; Yang, K, 2019) |
| "Many chemical drugs have been used to treat pulmonary hypertension, but result in limited efficacy and several side effects, and these medications are not always available worldwide." | ( Amin, F; Jamialahmadi, T; Johnston, TP; Sahebkar, A; Yousefvand, S, 2021) |
| "Drugs to treat pulmonary hypertension include endothelin antagonists, phosphodiesterase type 5 inhibitors and prostacyclin, which is the most widely used to treat pediatric pulmonary hypertension." | ( Gu, L; Li, QW; Liu, HM; Wu, Y; Zhu, L, 2022) |
| "Options to treat pulmonary hypertension (PH) in neonates with bronchopulmonary dysplasia (BPD) are few and largely ineffective." | ( Aschner, JL; Avachat, C; Birnbaum, AK; Fike, CD; Sherwin, CM, 2023) |